Drug resistance of tyrosine kinase inhibitors in renal cell carcinoma
10.12092/j.issn.1009-2501.2025.01.012
- VernacularTitle:小分子抑制剂在治疗肾癌中的研究进展
- Author:
Hanxu QIAN
1
;
Yaxuan ZHAO
1
;
Yang YANG
1
;
Yin ZHANG
1
Author Information
1. 滨州医学院药学院,烟台 264003,山东
- Publication Type:Journal Article
- Keywords:
renal carcinoma;
drug resistance;
TKI;
tumor angiogenesis;
target therapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(1):100-109
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitors(TKIs)are the key agent in the treatment of renal cell carcino-ma(RCC)so far.Drugs such as sunitinib and sorafenib showed significant benefits RCC patients,however,the adverse effect,drug efficacy and drug resistance limited the use of these therapy.Espe-cially the drug resistant issue brings up a big chal-lenge for clinical practice,and the mechanisms un-derlying are still poorly understood.In recent years,new therapies have been combined with TKIs to improve the treatment outcome.Immuno-therapy,combination therapy with other TKIs,tar-geted nanoparticle delivery,and drug modification are widely studied to improve the efficacies of TKIs and regain the sensitivity.In this review,we sum-marizes the current understanding of TKI drug resis-tance and the approaches to regaining drug sensi-tivity.
